Table 1 Population characteristics vs. mTBI serum assay test
mTBI Serum Assay Test | ||||
|---|---|---|---|---|
Factor | Overall | Negative | Positive | p-value |
n (%) | 130 | 34 (26.2) | 96 (73.8) | 0.01 |
Age (average ± SD) | 54 ± 23 | 42.7 ± 13.9 | 57.7 ± 24.2 | < 0.001 |
Cardiopathy n (%) | 12 (9.2) | 2 (5.9) | 10 (10.4) | 0.73 |
Diabetes n (%) | 10 (7.7) | 1 (2.9) | 9 (9.4) | 0.45 |
Hypertension n (%) | 34 (26.2) | 3 (8.8) | 31 (32.3) | 0.007 |
Neurological Disease n (%) | 11 (8.5) | 2 (5.9) | 9 (9.4) | 0.72 |
Positive Head CT Scan | 7 (5.4) | 0 (0.0) | 7 (7.3) | < 0.001 |
Antiaggregant Therapy n (%) | 15 (11.5) | 3 (8.8) | 12 (12.5) | 0.75 |
GFAP Median [IQR] pg/mL | 35.65 [19.1–84.0] | 17.02 [14–23] | 54 [28–105] | < 0.001 |
UCH-L1 Median [IQR] pg/mL | 452.7 [275–901] | 206 [164–323] | 677 [383–956] | < 0.001 |
mTBI Assay Sensitivity % (95% CI) | 100 (64.5–100) | - | - | - |
mTBI Assay Specificity % (95% CI) | 27.6 (20.0-36.4) | - | - | - |
mTBI Assay NPV % (95% CI) | 100 (88–100) | - | - | - |